Preoperative Factors for Lymphovascular Invasion in Prostate Cancer: A Systematic Review and Meta-Analysis

Int J Mol Sci. 2024 Jan 10;25(2):856. doi: 10.3390/ijms25020856.

Abstract

Lymphovascular invasion (LVI) is one of the most important prognostic factors in prostate cancer (PCa) and is correlated with worse survival rates, biochemical recurrence (BCR), and lymph node metastasis (LNM). The ability to predict LVI preoperatively in PCa may be useful for proposing variations in the diagnosis and management strategies. We performed a systematic review and meta-analysis to identify preoperative clinicopathological factors that correlate with LVI in final histopathological specimens in PCa patients. Systematic literature searches of PubMed, Embase, and Web of Science were performed up to 31 January 2023. A total of thirty-nine studies including 389,918 patients were included, most of which were retrospective and single-center. PSA level, clinical T stage, and biopsy Gleason score were significantly correlated with LVI in PCa specimens. Meta-analyses revealed that these factors were the strongest predictors of LVI in PCa patients. Prostate volume, BMI, and age were not significant predictors of LVI. A multitude of preoperative factors correlate with LVI in final histopathology. Meta-analyses confirmed correlation of LVI in final histopathology with higher preoperative PSA, clinical T stage, and biopsy Gleason score. This study implies advancements in risk stratification and enhanced clinical decision-making, and it underscores the importance of future research dedicated to validation and exploration of contemporary risk factors in PCa.

Keywords: histopathological examination; lymphovascular invasion; meta-analysis; preoperative risk assessment; prognostic factors; prostate cancer; radical prostatectomy.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • Biopsy
  • Clinical Decision-Making
  • Humans
  • Male
  • Prostate-Specific Antigen*
  • Prostatic Neoplasms* / surgery
  • Retrospective Studies

Substances

  • Prostate-Specific Antigen